Oncolytics Biotech (NASDAQ:ONCY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
2026-04-01 11:32:42 ET
Oncolytics Biotech ( NASDAQ:ONCY – Get Free Report ) released its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02), Zacks reports.
Oncolytics Biotech Stock Performance
Oncolytics Biotech stock traded up $0.03 during midday trading on Wednesday, reaching $0.88. The stock had a trading volume of 143,902 shares, compared to its average volume of 1,327,262. The stock has a market capitalization of $93.31 million, a P/E ratio of -3.14 and a beta of 0.92. The firm’s fifty day simple moving average is $1.00 and its 200-day simple moving average is $1.06. Oncolytics Biotech has a 1-year low of $0.33 and a 1-year high of $1.51.
Insider Transactions at Oncolytics Biotech
In other Oncolytics Biotech news, Director Bernd R. Seizinger purchased 100,000 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was bought at an average cost of $1.04 per share, with a total value of $104,000.00. Following the purchase, the director directly owned 466,991 shares of the company’s stock, valued at $485,670.64. The trade was a 27.25% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link . Also, Director Patricia S. Andrews acquired 35,400 shares of the stock in a transaction dated Thursday, February 12th. The stock was acquired at an average price of $0.86 per share, for a total transaction of $30,444.00. Following the completion of the acquisition, the director directly owned 78,128 shares of the company’s stock, valued at $67,190.08. The trade was a 82.85% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure . In the last 90 days, insiders bought 404,282 shares of company stock worth $363,232. Insiders own 0.10% of the company’s stock.
Institutional Trading of Oncolytics Biotech
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new stake in Oncolytics Biotech during the third quarter worth about $535,000. XTX Topco Ltd bought a new position in Oncolytics Biotech in the fourth quarter valued at approximately $69,000. Virtu Financial LLC bought a new position in Oncolytics Biotech in the fourth quarter valued at approximately $68,000. Tocqueville Asset Management L.P. acquired a new position in shares of Oncolytics Biotech during the 4th quarter worth approximately $63,000. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of Oncolytics Biotech during the 4th quarter worth approximately $44,000. Institutional investors and hedge funds own 6.82% of the company’s stock.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.
Get Our Latest Stock Analysis on ONCY
About Oncolytics Biotech
( Get Free Report )
Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard?of?care treatments and immune checkpoint inhibitors.
Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non?small cell lung cancer and head and neck cancers.
Further Reading
NASDAQ: ONCY
ONCY Trading
-3.97% G/L:
$0.9651 Last:
1,444,958 Volume:
$1.02 Open:
